Zobrazeno 1 - 10
of 160
pro vyhledávání: '"D. Craig Brater"'
Autor:
Salim Shah, Bertram Pitt, D. Craig Brater, Peter U. Feig, Wen Shen, Fatima S. Khwaja, Christopher S. Wilcox
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 6, Iss 10 (2017)
BackgroundLoop diuretics are highly natriuretic but their short duration of action permits postdiuretic sodium retention, which limits salt loss unless dietary salt is severely restricted. We tested the hypothesis that a more prolonged duration of ac
Externí odkaz:
https://doaj.org/article/301dbdfc30f8426cb516ef89c605363a
Autor:
Robert D. Toto, D. Craig Brater, Nancy Gritter, Matthew J. Matava, Douglas E. Rollins, Anthony P. Yates, Robert Heyer, Theodore F. Schlegel
Publikováno v:
Sports Health
Ketorolac tromethamine (Toradol®) is a non-steroidal anti-inflammatory drug that has potent analgesic and anti-inflammatory properties. It can be administered orally, intravenously, intramuscularly, or via a nasal route. Ketorolac injections have be
Autor:
Kye Min Kim, Yan Ding, Wanzhu Tu, Michael D. Murray, David A. Flockhart, D. Craig Brater, Jason D. Robarge
Publikováno v:
European Journal of Clinical Pharmacology. 68:1483-1491
To test for associations between genetic polymorphisms of adrenergic receptors (AR) and other candidate genes and healthcare utilization in heart failure patients, taking into account other important factors, such as medication adherence.One year-hos
Autor:
D. Craig Brater
Publikováno v:
Seminars in Nephrology. 31:483-494
All diuretics except spironolactone exert their effects from the lumen of the nephron. Thus, to exert an effect, they must reach the urine. Pharmacokinetics (PK) describes this access. Different edematous disorders can affect access to this site of a
Autor:
Henry Krum, Loren Laine, Sean P. Curtis, Gary Swergold, Amarjot Kaur, Hongwei Wang, Paul M. Peloso, Christopher P. Cannon, D. Craig Brater, Matthew R. Weir, Steven S. Smugar, Arnold R. Gammaitoni
Publikováno v:
Cardiovascular Therapeutics. 30:342-350
SUMMARY Introduction: The increased thrombotic cardiovascular (CV) risk in trials of cyclo- oxygenase-2 (COX-2) inhibitors versus placebo, and the apparent similar risk with nons- teroidal antiinflammatory drugs (NSAIDs), may be related to their pote
Publikováno v:
Clinical and Translational Science. 4:80-83
Autor:
Daoqin Bi, Louis R. Cantilena, D. Craig Brater, Michael J. Roy, Ronnie Beboso, Corina van de Pol, James M. Veazey, Michael A. Riel, Caron Kerr, Khadeeja Pruett, Colin Ohrt, Kevin J. Leary
Publikováno v:
The American Journal of Tropical Medicine and Hygiene. 81:356-362
A randomized, double-blind, placebo-controlled study was conducted to assess the effect of tafenoquine, 200 mg weekly for 6 months on ophthalmic and renal safety. This trial was carried out after observations in previous clini- cal trials that tafeno
Autor:
D. Craig Brater, Howard F. Morrelli
Publikováno v:
Acta Medica Scandinavica. 209:79-85
Reviews of large series of patients with digitalis-induced arrhythmias create a seeming paradox: Hypokalemia is infrequently associated with digitalis-induced arrhythmias but the clinical benefit of supplementation of potassium for most digitalis-ind
Autor:
Gary Swergold, Sean P. Curtis, D. Craig Brater, Hongwei Wang, Steven S. Smugar, Amarjot Kaur, Loren Laine, Matthew R. Weir, Henry Krum, Christopher P. Cannon
Publikováno v:
Journal of Hypertension. 27:886-893
To evaluate the hypertensive effects of etoricoxib and diclofenac relative to baseline hypertension risk factors in arthritis patients.Multivariate analysis of data from the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study (n
Autor:
D. Craig Brater, Maria Malmenäs, Ann Hedman, Bo Odlind, Lars I. Andersson, Gunilla Huledal, Bror Jonzon
Publikováno v:
Clinical Pharmacology & Therapeutics. 77:437-450
Background Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase (COX) and can thereby reduce renal function, especially with respect to solute excretion and renal perfusion. AZD3582 [4-(nitrooxy)butyl-(2S)-2-(6-methoxy-2-naphthyl)prop